Marinomed Biotech AG secures licensure with leading Consumer Health Care player for the distribution of Carragelose® products in Europe
Marinomed Biotech AG announces results for the first quarter of 2024
Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios
Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets
![](/fileadmin/_processed_/2/b/csm_Lucia_Mayr-Harting_321f1c9a5a.jpg)
Lucia Ziegler, MSc
Head of Investor & Public Relations